{"id":48400,"date":"2025-08-06T17:51:08","date_gmt":"2025-08-06T17:51:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/48400\/"},"modified":"2025-08-06T17:51:08","modified_gmt":"2025-08-06T17:51:08","slug":"some-wegovy-prescriptions-redirected-to-pharmacies-that-signed-exclusive-deals-with-insurers","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/48400\/","title":{"rendered":"Some Wegovy prescriptions redirected to pharmacies that signed exclusive deals with insurers"},"content":{"rendered":"<p class=\"c-article-body__text text-pr-5\">Some patients who take the popular weight-loss drug Wegovy are having their prescriptions redirected to <a href=\"https:\/\/www.theglobeandmail.com\/topics\/pharmaceutical-industry\/\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/www.theglobeandmail.com\/topics\/pharmaceutical-industry\/\">pharmacies<\/a> that have signed exclusive deals with their group benefit insurers, the most high-profile example yet of a controversial industry practice called preferred pharmacy networks, or PPNs.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Pharmacists in both Alberta and Ontario told The Globe and Mail about multiple incidents where drug claims for Wegovy have been rejected by insurance companies for reimbursement under group benefit plans. In most cases, pop-up messages at pharmacy checkouts alert patients that they have to contact a preferred pharmacy in order to receive their medication.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Insurers argue that they create PPNs to ensure certain service standards and to control costs for plan sponsors by negotiating lower pharmacy markups and fees. Pharmacies \u2013 particularly independent ones left out of networks \u2013 argue the exclusivity deals reduce patient autonomy and can leave patients filling prescriptions at multiple different pharmacies, depending on how the PPNs treat each drug.<\/p>\n<p class=\"c-article-body__text text-pr-5\">The Ontario government recently proposed options to regulate PPNs and has carried out two public consultations in the past year.<\/p>\n<p class=\"c-article-body__text text-pr-5\">PPNs are most commonly used for what insurers call \u201cspecialty drugs.\u201d While there is no universal industry definition of a specialty drug, it typically refers to high-cost drugs that can cost $10,000 or more a year. Insurers often say only a single-digit percentage of plan members take these drugs and are affected by PPN arrangements.<\/p>\n<p class=\"c-article-body__text mv-16 l-inset text-pb-8\" data-sophi-feature=\"interstitial\"><a href=\"https:\/\/www.theglobeandmail.com\/business\/article-life-insurance-industry-exclusivity-deals-ppns-group-plans\/\" rel=\"nofollow noopener\" target=\"_blank\">Insurers oppose Ontario\u2019s proposed restrictions on exclusivity deals with pharmacies<\/a><\/p>\n<p class=\"c-article-body__text text-pr-5\">Ozempic and Wegovy \u2013 two related products made by Danish drug maker Novo Nordisk <a href=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/NVO-N\/\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/NVO-N\/\">NVO-N<\/a> primarily to treat diabetes and obesity \u2013 are different from other specialty drugs in that they are much cheaper, costing a few hundred dollars a month. <\/p>\n<p class=\"c-article-body__text text-pr-5\">But they can contribute significantly to a plan sponsor\u2019s costs because they are high-volume. Ozempic is by far the bestselling prescription drug in Canada, with sales of more than $2.5-billion at retail pharmacies last year, nearly triple the next bestselling drug.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Many plan advisers \u2013 who help employers negotiate the renewal of group benefit plans \u2013 say the sharp rise in usage of these drugs is putting serious pressure on drug-plan sustainability. Some companies have already set maximum coverage limits. <\/p>\n<p class=\"c-article-body__text text-pr-5\">Joelle Walker, executive vice-president of strategy, operations and public affairs at the Canadian Pharmacists Association, said the fact that such a popular drug is now being caught up in PPNs is concerning.<\/p>\n<p class=\"c-article-body__text text-pr-5\">\u201cThe goalposts keep changing\u201d for what is considered a specialty drug, she said.<\/p>\n<p class=\"c-article-body__text mv-16 l-inset text-pb-8\" data-sophi-feature=\"interstitial\"><a href=\"https:\/\/www.theglobeandmail.com\/life\/article-prescription-drug-costs-are-forcing-canadians-to-make-dangerous-trade\/\" rel=\"nofollow noopener\" target=\"_blank\">Prescription drug costs are forcing Canadians to make dangerous trade-offs<\/a><\/p>\n<p class=\"c-article-body__text text-pr-5\">GreenShield Canada, which offers group benefit insurance plans, recently moved Wegovy into its closed PPN, which means that patients on the drug will have their claims reimbursed only if they buy it at in-network pharmacies.<\/p>\n<p class=\"c-article-body__text text-pr-5\">\u201cWegovy significantly increases total plan costs, due to the combination of its price and very high utilization,\u201d GreenShield spokesperson Mandy Mail said.<\/p>\n<p class=\"c-article-body__text text-pr-5\">The insurer said Wegovy claims were, on average, $5,100 annually a patient, more than five times higher than the average drug claimant.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Ms. Mail also said GreenShield will reassess the policy when <a href=\"https:\/\/www.theglobeandmail.com\/business\/article-generic-version-of-ozempic-wegovy-to-launch-in-canada-by-hims-hers\/\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/www.theglobeandmail.com\/business\/article-generic-version-of-ozempic-wegovy-to-launch-in-canada-by-hims-hers\/\">cheaper generics hit the market in Canada next year<\/a>.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Bruce Winston, senior director of advocacy at Neighbourly Pharmacy, a national chain, said a patient at one of its Alberta pharmacies recently had their prescriptions steered away by a mail-order pharmacy run by Express Scripts Canada. The patient, who has drug insurance through Sun Life Financial Inc. <a href=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/SLF-T\/\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/SLF-T\/\">SLF-T<\/a>, has diabetes and has been working with an Alberta pharmacist who is also a certified diabetes educator.<\/p>\n<p class=\"c-article-body__text mv-16 l-inset text-pb-8\" data-sophi-feature=\"interstitial\"><a href=\"https:\/\/www.theglobeandmail.com\/world\/article-most-patients-stop-using-wegovy-ozempic-for-weight-loss-within-two\/\" rel=\"nofollow noopener\" target=\"_blank\">Most patients stop using Wegovy, Ozempic for weight loss within two years, analysis finds<\/a><\/p>\n<p class=\"c-article-body__text text-pr-5\">Shortly after being prescribed Wegovy, the patient was contacted by Express Scripts Canada asking to transfer the Wegovy prescription to an Express Scripts pharmacy in order to save money. When the patient declined, they were told their insurance plan required the patient to fill their gastric inhibitory polypeptide and GLP-1 type prescriptions at an Express Scripts pharmacy.<\/p>\n<p class=\"c-article-body__text text-pr-5\">\u201cInitially, PPNs were concentrating on specialty high-cost drugs, but within the last few years, and for sure within mail-order pharmacies, it\u2019s gone well beyond high-cost drugs to regular medications,\u201d Mr. Winston said in an interview.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Sun Life said it does not require Wegovy prescriptions (or any other medication) to be filled only at a pharmacy in its preferred network. In response to a question about the Alberta patient at a Neighbourly Pharmacy, Sun Life said it did not have the details of that case but that it could be because of how the patient\u2019s employer designed their drug plan.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Express Scripts Canada did not respond to a request for comment. <\/p>\n<p class=\"c-article-body__text text-pr-5\">The Globe also asked the two other biggest Canadian private health insurers \u2013 Manulife <a href=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/MFC-T\/\" target=\"_blank\" rel=\"nofollow noopener\" title=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/MFC-T\/\">MFC-T<\/a> and Canada Life <a href=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/LFE-T\/\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/www.theglobeandmail.com\/investing\/markets\/stocks\/LFE-T\/\">LFE-T<\/a> \u2013 if Wegovy or Ozempic were part of their PPNs.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Canada Life said it does not include Wegovy under its Health Case Management plan, the name it applies to its PPN. Manulife said Wegovy is not part of any closed PPN, although plan sponsors have control over their plan designs.<\/p>\n<p class=\"c-article-body__text text-pr-5\">Novo Nordisk did not respond directly to questions about whether the company is aware of its products being directed through PPNs, but said it is \u201cfocused on improving access\u201d to its medicines.<\/p>\n<p class=\"c-article-body__text text-pr-5\">\u201cNovo Nordisk Canada supplies products to wholesalers for distribution to pharmacies and then to patients,\u201d senior director of communications Kate Hanna said in an e-mail.<\/p>\n","protected":false},"excerpt":{"rendered":"Some patients who take the popular weight-loss drug Wegovy are having their prescriptions redirected to pharmacies that have&hellip;\n","protected":false},"author":2,"featured_media":48401,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[64,63,137,490,41183],"class_list":{"0":"post-48400","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-au","9":"tag-australia","10":"tag-health","11":"tag-medication","12":"tag-ne-i"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/48400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=48400"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/48400\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/48401"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=48400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=48400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=48400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}